What this evidence supports
VITAL-H plans a phase 3 hybrid trial of repurposed FDA-approved drugs to establish a path for testing aging therapeutics.
What it does not establish
The trial is prospective. Existing approvals for the repurposed drugs do not establish approval for aging or healthspan, and the source reports no enrollment, effect, safety finding, new indication, or regulatory result.
Answer-ready summary
VITAL-H is designed to test whether repurposed drugs can improve aging-related outcomes within a regulatory pathway.
Record details
- Decision priority
- Watch
- Current status
- Current ARPA-H award description · phase 3 hybrid trial prospective · no results reported
- Evidence tracks
- Interventions · Human outcomes
- Source authority
- Primary/authoritative
- Source organization
- ARPA-H
- Evidence design
- Federal award description
- Applicability
- Applicable to decisions about the stated program, policy, standard, or development context; not evidence of clinical benefit beyond the cited scope.
- Confidence for the stated claim
- High
- Freshness
- Current
- Record date
- 2026-02-24
- Source date (award start)
- 2026-02-24
- Last verified
- 2026-09-03
- Review due
- 2026-10-03 or sooner if the cited source changes.
- Version
- 1.1
- Revision state
- Version 1.1 strengthens the prospective-trial and existing-approval limits and records the September 3, 2026 re-verification and February 24, 2026 award-start source date; the underlying VITAL-H plan is unchanged.
Evidence record fields
- Claim supported
- VITAL-H plans a phase 3 hybrid trial of repurposed FDA-approved drugs to establish a path for testing aging therapeutics.
- Source type and design
- Federal award description
- Population and setting
- Not a participant-level clinical-study population in this source type. The program, policy, regulatory, standards, or research context described by the cited source.
- Intervention/exposure and comparator
- Not evaluated as a comparative intervention or exposure in the cited administrative or program source. No comparator is reported for this source-bounded claim.
- Outcome or endpoint
- The program, policy, regulatory, standards, or development state stated in the claim supported; no clinical outcome is inferred.
- Follow-up duration
- No clinical follow-up duration is reported for this source-bounded claim.
- Effect estimate and uncertainty
- No clinical effect estimate is reported. No statistical uncertainty estimate is reported; uncertainty is bounded through the source scope and stated limitations.
- Harms/adverse events
- No harms or adverse-event analysis is reported for this source-bounded administrative or program claim.
- Missing data and attrition
- Not reported; this record does not analyze participant-level data. Not applicable or not reported; no longitudinal participant cohort is analyzed.
- Bias/limitations
- The trial is prospective. Existing approvals for the repurposed drugs do not establish approval for aging or healthspan, and the source reports no enrollment, effect, safety finding, new indication, or regulatory result.
- Applicability/generalizability
- Applicable to decisions about the stated program, policy, standard, or development context; not evidence of clinical benefit beyond the cited scope.
- Funding/conflicts
- Funding or sponsorship is recorded only where the cited source and claim state it; otherwise it is not assessed in this record. No conflict-of-interest assessment is reported for this administrative or program-source record.
- Replication or corroboration
- The administrative or program claim is anchored to the cited authoritative source; independent clinical replication is not implied.
- Decision use
- Use as source-bounded context for Researchers, Innovators, Funders/investors, Policymakers, Clinicians; do not use as stand-alone evidence of safety, efficacy, coverage, endorsement, or scaled adoption.
- Last reviewed / review due
- Last reviewed 2026-09-03; review due 2026-10-03 or sooner if the cited source changes.
For this decision
Researchers · Innovators · Funders/investors · Policymakers · Clinicians